Naresh Mori, MD
Cardiovascular Disease · Rock Hill, SCNPI 1629281282
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.6% of the total across 177 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,001, 2.5 times the $809 reported in 2019.
Across 177 payments — averaging $46.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$1K
- Boston Scientific$905
- Abbott$641
- AstraZeneca$475
- Edwards Lifesciences$427
- Johnson & Johnson$373
- plus $4K from 37 others
Across 13 payments — averaging $30,781 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$322K
- Ionis Pharmaceuticals, Inc.$47K
- AstraZeneca$31K
What the payments were for
- Travel & lodging$6688%
- Food & beverage$7,52492%
- Education$240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVVIGO Guidance System$612
- (9520) IGT Devices Undivided$583
- (6574) Coronary Other$380
- Indigo System$285
- GUIDELINER$278
- XARELTO$260
- Kerendia$242
- FARXIGA$238
- Diamondback Peripheral$221
- Inspire Upper Airway Stimulation System$140
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$137
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$130
- Impella$127
- Vascepa$125
- FUROSCIX$125
- ARCALYST$123
- BRILINTA$122
- Ozempic$121
- CardioMEMS HF System$120
- Edwards SAPIEN 3 Transcatheter Heart Valve$113
How this compares
$8,216 in reported general payments places this provider in the 70th percentile of 257 cardiovascular disease providers in South Carolina.
See all cardiovascular disease providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 30 | $731,959 |
| EliquisApixaban | 423 | $508,273 |
| OpsumitMacitentan | 24 | $374,693 |
| AdempasRiociguat | 11 | $154,964 |
| CamzyosMavacamten | 21 | $144,542 |
| EntrestoSacubitril/Valsartan | 98 | $125,191 |
| JardianceEmpagliflozin | 124 | $120,047 |
| XareltoRivaroxaban | 96 | $105,066 |
| FarxigaDapagliflozin Propanediol | 86 | $94,415 |
| BrilintaTicagrelor | 43 | $31,865 |
| MultaqDronedarone Hcl | 14 | $19,448 |
| OzempicSemaglutide | 14 | $15,172 |
| MounjaroTirzepatide | 11 | $12,915 |
| NexlizetBempedoic Acid/Ezetimibe | 17 | $10,855 |
| Metoprolol Succinate | 424 | $5,250 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $256 | $1,106,65254 claims |
| PfizerEliquis | $70 | $508,273423 claims |
| BayerAdempas | $302 | $154,96411 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $224 | $144,54221 claims |
| AstraZenecaFarxiga, Brilinta | $475 | $126,280129 claims |
| NovartisEntresto | $270 | $125,19198 claims |
| Boehringer IngelheimJardiance | $170 | $120,047124 claims |
| Johnson & JohnsonXarelto | $373 | $105,06696 claims |
| Sanofi-aventis U.S. LLCMultaq | $50 | $19,44814 claims |
| Novo NordiskOzempic | $121 | $15,17214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 257 cardiovascular disease providers in South Carolina.
Other cardiovascular disease in Rock Hill
- Murad AbdelsalamRock Hill$21K
- Robert BiedermanCharleston$775K
- Darren SidneyNorth Charleston$129K
- Priyanka BhattacharyaCharleston$107K
- Gregory SanGreenville$88K
- David McNeelyGreenville$78K
- Gregory EavesAiken$65K
- James SmithCharleston$64K
- Christopher SalmonGreenville$54K
- Ricky HendersonAnderson$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.